Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 27:13:853410.
doi: 10.3389/fmicb.2022.853410. eCollection 2022.

Atypical Antibody Dynamics During Human Coronavirus HKU1 Infections

Affiliations

Atypical Antibody Dynamics During Human Coronavirus HKU1 Infections

Ferdyansyah Sechan et al. Front Microbiol. .

Abstract

Human coronavirus HKU1 (HCoV-HKU1) is one of the four endemic coronaviruses. It has been suggested that there is a difference in incidence, with PCR-confirmed HCoV-NL63 and HCoV-OC43 infections occurring more commonly, whereas HCoV-HKU1 is the least seen. Lower incidence of HCoV-HKU1 infection has also been observed in serological studies. The current study aimed to investigate antibody dynamics during PCR-confirmed HCoV-HKU1 infections using serum collected during infection and 1 month later. We expressed a new HCoV-HKU1 antigen consisting of both the linker and carboxy-terminal domain of the viral nucleocapsid protein and implemented it in ELISA. We also applied a spike-based Luminex assay on serum samples from PCR-confirmed infections by the four endemic HCoVs. At least half of HCoV-HKU1-infected subjects consistently showed no antibody rise via either assay, and some subjects even exhibited substantial antibody decline. Investigation of self-reported symptoms revealed that HCoV-HKU1-infected subjects rated their illness milder than subjects infected by other HCoVs. In conclusion, HCoV-HKU1 infections reported in this study displayed atypical antibody dynamics and milder symptoms when compared to the other endemic HCoVs.

Keywords: HCoV-229E; HCoV-HKU1; HCoV-NL63; HCoV-OC43; IgG response; endemic seasonal coronavirus; nucleocapsid protein; spike protein.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
(A) Location of Nt-, Ct-, and linker (L)-domain of HCoV-HKU1 N as determined by pairwise alignment with HCoV-OC43, as well as the comparison of size between HKU1-NLCt and the HKU1-NCt antigen. (B) Multiple alignment of the nucleocapsid L domain of HCoV-NL63, HCoV-229E, HCoV-OC43, and HCoV-HKU1. The symbols below the aligned amino acid sequence represent the consensus symbol of amino acid residue at each position: asterisks (*) denotes fully conserved residue, colons (:) denotes amino acid residues with strongly similar property, periods (.) denotes amino acid residues with weakly similar property, and the absence of symbol denotes completely different property.
FIGURE 2
FIGURE 2
(A) V1-V2 Fold change in antibody values of 54 subjects with PCR-confirmed endemic HCoV infection, as assayed with ELISA with matched N antigen. For HCoV-HKU1-infections, both HKU1-NLCt (half-filled red circles) and HKU1-NCt (full red circles) were used for the N assay. Dotted line represents cutoff of significant antibody rise (fold change of 1.40 or higher). The NCt ELISA fold change values for all four endemic coronaviruses have been published previously Edridge et al. (2020). (B) V1-V2 Fold change in antibody values using matched S antigens for each HCoV infection in the S-Luminex assay. Dotted line represents the cutoff of significant S-antibody rise (fold change of 2.01 or higher).

References

    1. Al-Khannaq M. N., Ng K. T., Oong X. Y., Pang Y. K., Takebe Y., Chook J. B., et al. (2016). Molecular epidemiology and evolutionary histories of human coronavirus OC43 and HKU1 among patients with upper respiratory tract infections in Kuala Lumpur, Malaysia. Virol. J. 13 1–12. 10.1186/s12985-016-0488-4 - DOI - PMC - PubMed
    1. Brochot E., Demey B., Touzé A., Belouzard S., Dubuisson J., Schmit J. L., et al. (2020). Anti-spike, anti-nucleocapsid and neutralizing antibodies in sars-cov-2 inpatients and asymptomatic individuals. Front. Microbiol. 11:584251. 10.3389/fmicb.2020.584251 - DOI - PMC - PubMed
    1. Brouwer P. J. M., Brinkkemper M., Maisonnasse P., Dereuddre-Bosquet N., Grobben M., Claireaux M., et al. (2021). Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell 184 1188.e–1200.e. 10.1016/j.cell.2021.01.035 - DOI - PMC - PubMed
    1. Callow K. A. (1985). Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection. J. Hyg. Camb. 95, 173–189. 10.1017/S0022172400062410 - DOI - PMC - PubMed
    1. Cui J., Li F., Shi Z. L. (2019). Origin and evolution of pathogenic coronaviruses. Nature Rev. Microbiol. 17 181–192. 10.1038/s41579-018-0118-9 - DOI - PMC - PubMed

LinkOut - more resources